Maria Cristina Costa de Almeida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maria Cristina Costa de Almeida has a total of 117 co-authors. Here are the top co-authors by number of shared publications:
- Gláucia Maria Moraes de Oliveira
Department of Women's Cardiology of the Brazilian Society of Cardiology, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
11 shared publications - Larissa Neto Espíndola
Hospital Santa Izabel, Brasil; Hospital Municipal de Salvador, Brasil
11 shared publications - Marildes Luiza de Castro
Faculdade de Medicina da Universidade Federal de Minas Gerais, Brasil
11 shared publications - Celi Marques-Santos
Universidade Tiradentes, Brasil; Hospital São Lucas, Brasil
9 shared publications - Maria Elizabeth Navegantes Caetano Costa
Centro Universitário do Estado Pará (CESUPA), Brasil
9 shared publications - Alexandre Jorge Gomes de Lucena
Hospital Agamenon Magalhães, Brasil
8 shared publications
Latest Publications
- Open Access
- 18 November 2025
- Published by Federação das Associações de Ginecologia e Obstetrícia in Revista Brasileira de Ginecologia e Obstetrícia
- Vol. 47
Position Statement on Cardiometabolic Health Across the Woman's Life Course – 2025
1. Introduction Cardiometabolic health can be characterized by ideal levels of serum glucose and lipids and of blood pressure (BP) in association with low adiposity and cardiovascular risk (CVR). Usually, cardiometabolic health is the absence of metabolic dysfunction characteristic of some diseases, such as cardiovascular diseases (CVD), type 2 diabetes mellitus (T2DM), and metabolic syndrome […] 1. Introduction Cardiometabolic health can be characterized by ideal levels of serum glucose and lipids and of blood pressure (BP) in association with low adiposity and cardiovascular risk (CVR). Usually, cardiometabolic health is the absence of metabolic dysfunction characteristic of some diseases, such as cardiovascular diseases (CVD), type 2 diabetes mellitus (T2DM), and metabolic syndrome […]
- 18 November 2025
- Published by Federação das Associações de Ginecologia e Obstetrícia in Revista Brasileira de Ginecologia e Obstetrícia
- Vol. 47
Open AccessPosition Statement on Cardiometabolic Health Across the Woman's Life Course – 2025
1. Introduction Cardiometabolic health can be characterized by ideal levels of serum glucose and lipids and of blood pressure (BP) in association with low adiposity and cardiovascular risk (CVR). Usually, cardiometabolic health is the absence of metabolic dysfunction characteristic of some diseases, such as cardiovascular diseases (CVD), type 2 diabetes mellitus (T2DM), and metabolic syndrome […] 1. Introduction Cardiometabolic health can be characterized by ideal levels of serum glucose and lipids and of blood pressure (BP) in association with low adiposity and cardiovascular risk (CVR). Usually, cardiometabolic health is the absence of metabolic dysfunction characteristic of some diseases, such as cardiovascular diseases (CVD), type 2 diabetes mellitus (T2DM), and metabolic syndrome […]
- Open Access
- 1 January 2025
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 122 (9)
Position Statement on Cardiometabolic Health Across the Woman's Life Course – 2025
Table of contents […] Position Statement on Cardiometabolic Health Across the Woman’s Life Course – 2025 Table of contents […] Position Statement on Cardiometabolic Health Across the Woman’s Life Course – 2025
- 1 January 2025
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 122 (9)
Open AccessPosition Statement on Cardiometabolic Health Across the Woman's Life Course – 2025
Table of contents […] Position Statement on Cardiometabolic Health Across the Woman’s Life Course – 2025 Table of contents […] Position Statement on Cardiometabolic Health Across the Woman’s Life Course – 2025
- Open Access
- 1 January 2025
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 122 (9) , e20250615
Posicionamento sobre a Saúde Cardiometabólica ao Longo do Ciclo de Vida da Mulher – 2025
Sumário […] Posicionamento sobre a Saúde Cardiometabólica ao Longo do Ciclo de Vida da Mulher – 2025 Sumário […] Posicionamento sobre a Saúde Cardiometabólica ao Longo do Ciclo de Vida da Mulher – 2025
- 1 January 2025
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 122 (9) , e20250615
Open AccessPosicionamento sobre a Saúde Cardiometabólica ao Longo do Ciclo de Vida da Mulher – 2025
Sumário […] Posicionamento sobre a Saúde Cardiometabólica ao Longo do Ciclo de Vida da Mulher – 2025 Sumário […] Posicionamento sobre a Saúde Cardiometabólica ao Longo do Ciclo de Vida da Mulher – 2025
- Open Access
- 7 October 2024
- Published by Federação das Associações de Ginecologia e Obstetrícia in Revista Brasileira de Ginecologia e Obstetrícia
- Vol. 46
Brazilian Guideline on Menopausal Cardiovascular Health – 2024
1. Introduction After the publication of the results from the Women’s Health Initiative (WHI) clinical trial in 2002 showing more risks than benefits to female health with estrogen (alone or combined with progestin) use to control menopausal signs and symptoms, there has been a progressive and sustained decline in the prescription of those drugs.– In […] 1. Introduction After the publication of the results from the Women’s Health Initiative (WHI) clinical trial in 2002 showing more risks than benefits to female health with estrogen (alone or combined with progestin) use to control menopausal signs and symptoms, there has been a progressive and sustained decline in the prescription of those drugs.– In […]
- 7 October 2024
- Published by Federação das Associações de Ginecologia e Obstetrícia in Revista Brasileira de Ginecologia e Obstetrícia
- Vol. 46
Open AccessBrazilian Guideline on Menopausal Cardiovascular Health – 2024
1. Introduction After the publication of the results from the Women’s Health Initiative (WHI) clinical trial in 2002 showing more risks than benefits to female health with estrogen (alone or combined with progestin) use to control menopausal signs and symptoms, there has been a progressive and sustained decline in the prescription of those drugs.– In […] 1. Introduction After the publication of the results from the Women’s Health Initiative (WHI) clinical trial in 2002 showing more risks than benefits to female health with estrogen (alone or combined with progestin) use to control menopausal signs and symptoms, there has been a progressive and sustained decline in the prescription of those drugs.– In […]
- Open Access
- 12 August 2024
- Published by Sociedade Brasileira de Cardiologia in International Journal of Cardiovascular Sciences
- Vol. 37
Cardiac Amyloidosis in Women: An Underappreciated Diagnosis
Cardiac amyloidosis (CA) is an infiltrative cardiomyopathy that affects the heart mostly in two forms: immunoglobulin light chain amyloidosis (AL-CM) and transthyretin amyloidosis. Transthyretin amyloid cardiomyopathy (ATTR-CM) predominantly affects the elderly population, mainly men (about 70-80%), and usually manifests with symptoms of heart failure (HF). Despite technological advances in medicine, CA is still an underdiagnosed condition, especially in women, partly due to the known male predominance and high level of suspicion required for diagnosis. It is important to remember [...] Abstract Cardiac amyloidosis (CA) is an infiltrative cardiomyopathy that affects the heart mostly in two forms: immunoglobulin light chain amyloidosis (AL-CM) and transthyretin amyloidosis. Transthyretin amyloid cardiomyopathy (ATTR-CM) predominantly affects the elderly population, mainly men (about 70-80%), and usually manifests with symptoms of heart failure (HF). Despite technological advances in medicine, CA is still an underdiagnosed condition, especially in women, partly due to the known male predominance and high level of suspicion required for diagnosis. It is important to remember
- 12 August 2024
- Published by Sociedade Brasileira de Cardiologia in International Journal of Cardiovascular Sciences
- Vol. 37
Open AccessCardiac Amyloidosis in Women: An Underappreciated Diagnosis
Cardiac amyloidosis (CA) is an infiltrative cardiomyopathy that affects the heart mostly in two forms: immunoglobulin light chain amyloidosis (AL-CM) and transthyretin amyloidosis. Transthyretin amyloid cardiomyopathy (ATTR-CM) predominantly affects the elderly population, mainly men (about 70-80%), and usually manifests with symptoms of heart failure (HF). Despite technological advances in medicine, CA is still an underdiagnosed condition, especially in women, partly due to the known male predominance and high level of suspicion required for diagnosis. It is important to remember [...] Abstract Cardiac amyloidosis (CA) is an infiltrative cardiomyopathy that affects the heart mostly in two forms: immunoglobulin light chain amyloidosis (AL-CM) and transthyretin amyloidosis. Transthyretin amyloid cardiomyopathy (ATTR-CM) predominantly affects the elderly population, mainly men (about 70-80%), and usually manifests with symptoms of heart failure (HF). Despite technological advances in medicine, CA is still an underdiagnosed condition, especially in women, partly due to the known male predominance and high level of suspicion required for diagnosis. It is important to remember
- Open Access
- 1 January 2024
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 121 (11)
The Choice of Antiplatelet Dual Combination in Coronary Artery Disease: Is this Just a Question of Balance between ischemic Burden and Bleeding Risk?
- 1 January 2024
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 121 (11)
Open AccessThe Choice of Antiplatelet Dual Combination in Coronary Artery Disease: Is this Just a Question of Balance between ischemic Burden and Bleeding Risk?
- Open Access
- 1 January 2024
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 121 (11)
Escolha de Dupla Antiagregação na Doença Arterial Coronariana: Apenas uma Questão de Equilíbrio entre a Carga Isquêmica e o Risco de Sangramento?
- 1 January 2024
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 121 (11)
Open AccessEscolha de Dupla Antiagregação na Doença Arterial Coronariana: Apenas uma Questão de Equilíbrio entre a Carga Isquêmica e o Risco de Sangramento?
- Open Access
- 1 January 2024
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 121 (7)
Brazilian Guideline on Menopausal Cardiovascular Health – 2024
1. Introduction After the publication of the results from the Women’s Health Initiative (WHI) clinical trial in 2002 showing more risks than benefits to female health with estrogen (alone or combined with progestin) use to control menopausal signs and symptoms, there has been a progressive and sustained decline in the prescription of those drugs.– In the United States, there was an increase in the prescription of menopausal hormone therapy (MHT) from 16 million in 1966 to 90 million in 1999,– [...] 1. Introduction After the publication of the results from the Women’s Health Initiative (WHI) clinical trial in 2002 showing more risks than benefits to female health with estrogen (alone or combined with progestin) use to control menopausal signs and symptoms, there has been a progressive and sustained decline in the prescription of those drugs.– In the United States, there was an increase in the prescription of menopausal hormone therapy (MHT) from 16 million in 1966 to 90 million in 1999,–
- 1 January 2024
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 121 (7)
Open AccessBrazilian Guideline on Menopausal Cardiovascular Health – 2024
1. Introduction After the publication of the results from the Women’s Health Initiative (WHI) clinical trial in 2002 showing more risks than benefits to female health with estrogen (alone or combined with progestin) use to control menopausal signs and symptoms, there has been a progressive and sustained decline in the prescription of those drugs.– In the United States, there was an increase in the prescription of menopausal hormone therapy (MHT) from 16 million in 1966 to 90 million in 1999,– [...] 1. Introduction After the publication of the results from the Women’s Health Initiative (WHI) clinical trial in 2002 showing more risks than benefits to female health with estrogen (alone or combined with progestin) use to control menopausal signs and symptoms, there has been a progressive and sustained decline in the prescription of those drugs.– In the United States, there was an increase in the prescription of menopausal hormone therapy (MHT) from 16 million in 1966 to 90 million in 1999,–
- Open Access
- 1 January 2024
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 121 (7) , e20240478
Diretriz Brasileira sobre a Saúde Cardiovascular no Climatério e na Menopausa – 2024
1. Introdução Após a publicação dos resultados de ensaio clínico realizado pelo Women’s Health Initiative (WHI) em 2002, demonstrando que há mais riscos do que benefícios para a saúde feminina com a utilização de estrogênio (isolado ou combinado a progestagênio) para o controle dos sinais e sintomas da menopausa, houve uma diminuição progressiva e sustentada na prescrição desses medicamentos.– Nos Estados Unidos, havia ocorrido um aumento de prescrições da terapia hormonal da menopausa (THM) de 16 milhões em 1966 para [...] 1. Introdução Após a publicação dos resultados de ensaio clínico realizado pelo Women’s Health Initiative (WHI) em 2002, demonstrando que há mais riscos do que benefícios para a saúde feminina com a utilização de estrogênio (isolado ou combinado a progestagênio) para o controle dos sinais e sintomas da menopausa, houve uma diminuição progressiva e sustentada na prescrição desses medicamentos.– Nos Estados Unidos, havia ocorrido um aumento de prescrições da terapia hormonal da menopausa (THM) de 16 milhões em 1966 para
- 1 January 2024
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 121 (7) , e20240478
Open AccessDiretriz Brasileira sobre a Saúde Cardiovascular no Climatério e na Menopausa – 2024
1. Introdução Após a publicação dos resultados de ensaio clínico realizado pelo Women’s Health Initiative (WHI) em 2002, demonstrando que há mais riscos do que benefícios para a saúde feminina com a utilização de estrogênio (isolado ou combinado a progestagênio) para o controle dos sinais e sintomas da menopausa, houve uma diminuição progressiva e sustentada na prescrição desses medicamentos.– Nos Estados Unidos, havia ocorrido um aumento de prescrições da terapia hormonal da menopausa (THM) de 16 milhões em 1966 para [...] 1. Introdução Após a publicação dos resultados de ensaio clínico realizado pelo Women’s Health Initiative (WHI) em 2002, demonstrando que há mais riscos do que benefícios para a saúde feminina com a utilização de estrogênio (isolado ou combinado a progestagênio) para o controle dos sinais e sintomas da menopausa, houve uma diminuição progressiva e sustentada na prescrição desses medicamentos.– Nos Estados Unidos, havia ocorrido um aumento de prescrições da terapia hormonal da menopausa (THM) de 16 milhões em 1966 para
- Open Access
- 29 August 2023
- Published by Sociedade Brasileira de Cardiologia in International Journal of Cardiovascular Sciences
- Vol. 36
One Size Does Not Fit All: The Need to Rethink the Metabolic Syndrome in Women
Metabolic syndrome (MetS) is increasing at epidemic proportions worldwide. MetS and its components are frequent among Brazilian women (41.8%). Women are affected by changes in adipose tissue distribution, lipid profile, insulin resistance (IR), and vascular remodeling during their lives. These changes result from the lack of estrogen after menopause. There have been various attempts to propose a uniform origin for the clustering of the MetS components, including genetics, IR, obesity, lifestyle, sleep disturbances, inflammation, fetal and neonatal programming, and [...] Abstract Metabolic syndrome (MetS) is increasing at epidemic proportions worldwide. MetS and its components are frequent among Brazilian women (41.8%). Women are affected by changes in adipose tissue distribution, lipid profile, insulin resistance (IR), and vascular remodeling during their lives. These changes result from the lack of estrogen after menopause. There have been various attempts to propose a uniform origin for the clustering of the MetS components, including genetics, IR, obesity, lifestyle, sleep disturbances, inflammation, fetal and neonatal programming, and
- 29 August 2023
- Published by Sociedade Brasileira de Cardiologia in International Journal of Cardiovascular Sciences
- Vol. 36
Open AccessOne Size Does Not Fit All: The Need to Rethink the Metabolic Syndrome in Women
Metabolic syndrome (MetS) is increasing at epidemic proportions worldwide. MetS and its components are frequent among Brazilian women (41.8%). Women are affected by changes in adipose tissue distribution, lipid profile, insulin resistance (IR), and vascular remodeling during their lives. These changes result from the lack of estrogen after menopause. There have been various attempts to propose a uniform origin for the clustering of the MetS components, including genetics, IR, obesity, lifestyle, sleep disturbances, inflammation, fetal and neonatal programming, and [...] Abstract Metabolic syndrome (MetS) is increasing at epidemic proportions worldwide. MetS and its components are frequent among Brazilian women (41.8%). Women are affected by changes in adipose tissue distribution, lipid profile, insulin resistance (IR), and vascular remodeling during their lives. These changes result from the lack of estrogen after menopause. There have been various attempts to propose a uniform origin for the clustering of the MetS components, including genetics, IR, obesity, lifestyle, sleep disturbances, inflammation, fetal and neonatal programming, and